Chicago Capital LLC Sells 32,540 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Chicago Capital LLC lessened its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 3.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 970,607 shares of the medical device company's stock after selling 32,540 shares during the period. Chicago Capital LLC owned 1.48% of Tandem Diabetes Care worth $34,961,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of TNDM. Dimensional Fund Advisors LP lifted its position in Tandem Diabetes Care by 35.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 56,200 shares of the medical device company's stock valued at $2,264,000 after purchasing an additional 14,664 shares during the period. Sei Investments Co. lifted its holdings in Tandem Diabetes Care by 108.4% in the second quarter. Sei Investments Co. now owns 36,150 shares of the medical device company's stock valued at $1,456,000 after buying an additional 18,801 shares during the period. Bank of Montreal Can boosted its stake in Tandem Diabetes Care by 123.5% in the second quarter. Bank of Montreal Can now owns 19,990 shares of the medical device company's stock valued at $837,000 after acquiring an additional 11,045 shares during the last quarter. AQR Capital Management LLC bought a new position in Tandem Diabetes Care in the second quarter valued at approximately $295,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Tandem Diabetes Care by 310.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 35,980 shares of the medical device company's stock worth $1,450,000 after acquiring an additional 27,208 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TNDM. Barclays raised their price target on Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an "overweight" rating in a research report on Friday, November 8th. Morgan Stanley upgraded Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and set a $45.00 target price on the stock in a report on Monday, December 2nd. Sanford C. Bernstein initiated coverage on Tandem Diabetes Care in a research note on Wednesday, November 6th. They issued an "outperform" rating and a $42.00 price target for the company. Canaccord Genuity Group reduced their price objective on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a "buy" rating on the stock in a research note on Thursday, November 7th. Finally, Citigroup decreased their price objective on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, Tandem Diabetes Care has a consensus rating of "Moderate Buy" and an average target price of $53.81.

Tandem Diabetes Care Stock Up 0.1 %

Tandem Diabetes Care stock traded up $0.05 during midday trading on Thursday, reaching $36.74. The stock had a trading volume of 771,164 shares, compared to its average volume of 905,119. The stock has a market capitalization of $2.41 billion, a P/E ratio of -19.04 and a beta of 1.32. The firm's fifty day simple moving average is $35.20 and its 200-day simple moving average is $37.27. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care, Inc. has a 1-year low of $22.03 and a 1-year high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $243.97 million for the quarter, compared to the consensus estimate of $224.14 million. During the same period last year, the company earned ($0.38) earnings per share. The firm's revenue was up 31.4% compared to the same quarter last year. As a group, analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the transaction, the director now directly owns 195,190 shares in the company, valued at $5,855,700. This trade represents a 4.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.20% of the stock is owned by insiders.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.